Last reviewed · How we verify

Alcohol withdrawal syndrome — Treatment Landscape & Competitive Intelligence

Alcohol withdrawal syndrome (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Alcohol withdrawal syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Tranxene clorazepate Ajenat Pharms Benzodiazepine GABA-A receptor alpha-1/beta-2/gamma-2 1972-01-01
Valium diazepam Generic (originally Roche) Benzodiazepine [EPC] Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2 1963-11-15
Chlordiazepoxide Hydrochloride CHLORDIAZEPOXIDE Bausch Health Benzodiazepine Histamine H1 receptor 1960-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Alcohol withdrawal syndrome
  2. Ajenat Pharms · 1 drug in Alcohol withdrawal syndrome
  3. Bausch Health · 1 drug in Alcohol withdrawal syndrome
  4. Generic (originally Roche) · 1 drug in Alcohol withdrawal syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Alcohol withdrawal syndrome:

Cite this brief

Drug Landscape (2026). Alcohol withdrawal syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/alcohol-withdrawal-syndrome. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing